#	Pagina
attuale pagina	/open-h2020/projects/210467/index.html

Opendata, web and dolomites

TIGITtherapy SIGNED

TIGIT therapy for cancer treatment

Total Cost €

EC-Contrib. €

Partnership

Views

TIGITtherapy project word cloud

Explore the words cloud of the TIGITtherapy project. It provides you a very rough idea of what is the project "TIGITtherapy" about.

immunotherapy previously constitutively anti alone mabs tumors ig expressed nk pharma vitro killer drugs receptor blockage tumor cell advancements lymphocytes market oncology inhibited captured vivo infiltrating tigittherapy recognizes tigit nectin2 companies erc 50 ligands inhibitory 2009 leads bacnk decade nearly bio therapies discovered pvr combination grant cancer poc group immune pd cells treating expression made natural antagonize tils checkpoint attracted either

Project "TIGITtherapy" data sheet

The following table provides information about the project.

Coordinator	THE HEBREW UNIVERSITY OF JERUSALEM Organization address address: EDMOND J SAFRA CAMPUS GIVAT RAM city: JERUSALEM postcode: 91904 website: www.huji.ac.il contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Israel [IL]
Total cost	150˙000 €
EC max contribution	150˙000 € (100%)
Programme	1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
Code Call	ERC-2016-PoC
Funding Scheme	ERC-POC
Starting year	2017
Duration (year-month-day)	from 2017-07-01 to 2018-12-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	THE HEBREW UNIVERSITY OF JERUSALEM THE HEBREW UNIVERSITY OF JERUSALEM Organization address address: EDMOND J SAFRA CAMPUS GIVAT RAM city: JERUSALEM postcode: 91904 website: www.huji.ac.il contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IL (JERUSALEM)	coordinator	150˙000.00

Map

Project objective

Treating tumors with immune-related therapies is one of the most exciting and promising advancements made in the past decade. Cancer immunotherapy drugs have captured nearly 50% of the overall oncology drugs market. TIGIT is an important checkpoint inhibitory receptor discovered by our group in 2009. It is constitutively expressed by various immune cells and its expression is further increased on tumor infiltrating lymphocytes (TILs). TIGIT recognizes two main ligands, PVR and Nectin2 that are highly expressed on various tumors. Blockage of TIGIT on TILs either alone or in combination with another checkpoint inhibitory receptor, PD-1, leads to increased T and Natural Killer (NK) cell activity in vitro and inhibited tumor growth in vivo. We developed 9 different anti-TIGIT mAbs during my BacNK ERC advanced grant and previously. In the POC grant TIGITtherapy, which already attracted interest from several bio pharma companies, I propose testing which of the 9 anti-TIGIT mAbs and TIGIT-Ig are able to antagonize TIGIT activity.

Publications

List of publications.
year	authors and title	journal	last update
2018	Moriya Gamliel, Debra Goldman-Wohl, Batya Isaacson, Chamutal Gur, Natan Stein, Rachel Yamin, Michael Berger, Myriam Grunewald, Eli Keshet, Yoach Rais, Chamutal Bornstein, Eyal David, Adam Jelinski, Iris Eisenberg, Caryn Greenfield, Arbel Ben-David, Tal Imbar, Ronit Gilad, Ronit Haimov-Kochman, David Mankuta, Matan Elami-Suzin, Ido Amit, Jacob H. Hanna, Simcha Yagel, Ofer Mandelboim Trained Memory of Human Uterine NK Cells Enhances Their Function in Subsequent Pregnancies published pages: 951-962.e5, ISSN: 1074-7613, DOI: 10.1016/j.immuni.2018.03.030	Immunity 48/5	2019-06-06
2018	Liat Dassa, Einat Seidel, Esther Oiknine-Djian, Rachel Yamin, Dana G. Wolf, Vu Thuy Khanh Le-Trilling, Ofer Mandelboim The Human Cytomegalovirus Protein UL148A Downregulates the NK Cell-Activating Ligand MICA To Avoid NK Cell Attack published pages: , ISSN: 0022-538X, DOI: 10.1128/jvi.00162-18	Journal of Virology 92/17	2019-06-06
2018	Dominik Schmiedel, Ofer Mandelboim NKG2D Ligandsâ€“Critical Targets for Cancer Immune Escape and Therapy published pages: , ISSN: 1664-3224, DOI: 10.3389/fimmu.2018.02040	Frontiers in Immunology 9	2019-06-06
2018	Tirtsah Toledano, Alon Vitenshtein, Noam Stern-Ginossar, Einat Seidel, Ofer Mandelboim Decay of the Stress-Induced Ligand MICA Is Controlled by the Expression of an Alternative 3â€² Untranslated Region published pages: 2819-2825, ISSN: 0022-1767, DOI: 10.4049/jimmunol.1700968	The Journal of Immunology 200/8	2019-06-06
2017	Yoav Charpak-Amikam, Tobias Kubsch, Einat Seidel, Esther Oiknine-Djian, Noemi Cavaletto, Rachel Yamin, Dominik Schmiedel, Dana Wolf, Giorgio Gribaudo, Martin Messerle, Luka Cicin-Sain, Ofer Mandelboim Human cytomegalovirus escapes immune recognition by NK cells through the downregulation of B7-H6 by the viral genes US18 and US20 published pages: , ISSN: 2045-2322, DOI: 10.1038/s41598-017-08866-2	Scientific Reports 7/1	2019-06-06
2018	Ariella Glasner, Assi Levi, Jonatan Enk, Batya Isaacson, Sergey Viukov, Shari Orlanski, Alon Scope, Tzahi Neuman, Claes D. Enk, Jacob H. Hanna, Veronika Sexl, Stipan Jonjic, Barbara Seliger, Laurence Zitvogel, Ofer Mandelboim NKp46 Receptor-Mediated Interferon-Î³ Production by Natural Killer Cells Increases Fibronectin 1 to Alter Tumor Architecture and Control Metastasis published pages: 107-119.e4, ISSN: 1074-7613, DOI: 10.1016/j.immuni.2017.12.007	Immunity 48/1	2019-06-06

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TIGITTHERAPY" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TIGITTHERAPY" are provided by the European Opendata Portal: CORDIS opendata.